NIAID Banner Logo Image

TB Drugs in Development


Drug ClassCompanyDrug NameAlt NameDrug StatusNotesAIDS#
Cell Wall Synthesis InhibitorSequellaSQ-109 Phase 2Completed 207396
Cell Wall Synthesis InhibitorAstraZeneca; Sanofi; Sumitomo Dainippon PharmaMerrem™ICI 194660; ICI 213689; MeropenemPhase 2Recruiting 007788
Cell Wall Synthesis InhibitorAsubio PharmaFaropenemFarom; ALP 201; BLA 857Phase 2Recruiting 545326
DNA Replication Inhibitor/TB Cell division inhibitorBayer; Schering-Plough MoxifloxacinMXFX; BAY 12-8039Phase 3Recruiting 070017
DNA Replication Inhibitor/TB Cell division inhibitorDaiichi Pharm; Sanofi-Aventis; Ortho-McneilLevofloxacinS-(-)-Ofloxacin; DR-3355; RWJ-25213; Cravit; L-Ofloxacin; LVX; Levaquin; TavanicPhase 3Terminated 002307
DNA Replication Inhibitor/TB Cell division inhibitorBayerFlagyl™Metronidazole; Bayer 5360; Methronidazole; MTZ; RP 8823; SC 10295; WagitranPhase 2Completed 007953
DNA Replication Inhibitor/TB Cell division inhibitorParke-Davis; Kyorin Pharm; PfizerTequin™Gatifloxacin; GTFX; BMS-206584; AM-1155; CG 5501; PD-135432; GATPhase 1/2Completed 044913
Intracellular NO ReleasePathogenesis Corp; ChironPretomanidPA-824Phase 3Recruiting 007331
Intracellular NO ReleaseGlobal Alliance for TB Drug DevelopmentTBA-354 Phase 1Recruiting 510946
Mycolic acid biosynthesis inhibitorOtsuka PharmDelamanidOPC-67683Phase 3Ongoing, Not Recruiting 182259
Protein Synthesis Inhibitor/TB growth InhibitorAstrazenecaAZD-5847 Phase 2aCompleted 554767
Protein Synthesis Inhibitor/TB growth InhibitorPharmacia & Upjohn, Inc.; PfizerSutezolidPNU-100480; PF-02341272Phase 2aCompleted 045415
Protein Synthesis Inhibitor/TB growth InhibitorsPharmacia & Upjohn, Inc.; PfizerZyvox™Linezolid; PNU-100766Phase 3Recruiting 070944
TB Cell division inhibitorMarion Merrel Dow; Sanofi-AventisPriftin™Rifapentine; MDL 473; RPE; RPT; Cyclopentyl rifampin; DL 473; R 77-3FDA approved in 2014 as part of combination therapy with isoniazid  007686

Last Updated: April 2015